{
    "ticker": "AADI",
    "name": "Aadi Bioscience, Inc.",
    "description": "Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative therapies for patients with genetically defined cancers. Founded in 2011 and headquartered in San Diego, California, Aadi is committed to advancing precision medicine through its innovative approach to drug development. The company's lead product candidate, AADI-001, is a novel treatment aimed at patients with tumors harboring specific genetic mutations, particularly in the mTOR pathway. This targeted therapy is designed to address unmet medical needs in oncology, offering hope to patients who have few treatment options available. Aadi is also exploring additional candidates in its pipeline that target other genetically defined cancers, leveraging its expertise in biomarker-driven approaches to oncology. The company's vision is to redefine cancer treatment by providing therapies that are tailored to the unique genetic profiles of patients, thereby maximizing efficacy and minimizing side effects. With a strong focus on research and development, Aadi aims to bring groundbreaking therapies to market that can improve outcomes for cancer patients worldwide.",
    "industry": [
        "Biopharmaceuticals",
        "Oncology"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2011",
    "website": "https://www.aadibio.com",
    "ceo": "Nina M. P.",
    "social_media": {
        "twitter": "https://twitter.com/aadibio",
        "linkedin": "https://www.linkedin.com/company/aadi-bioscience"
    },
    "investor_relations": "https://www.aadibio.com/investors",
    "key_executives": [
        {
            "name": "Nina M. P.",
            "position": "CEO"
        },
        {
            "name": "Ravi K. D. S.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "AADI-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Aadi Bioscience, Inc. | Precision Oncology",
        "meta_description": "Explore Aadi Bioscience, Inc., a leader in precision oncology focused on developing therapies for genetically defined cancers. Learn about their innovative approach and pipeline.",
        "keywords": [
            "Aadi Bioscience",
            "Oncology",
            "Biopharmaceuticals",
            "Precision Medicine",
            "AADI-001"
        ]
    },
    "faq": [
        {
            "question": "What is Aadi Bioscience known for?",
            "answer": "Aadi Bioscience is known for developing targeted therapies for patients with genetically defined cancers."
        },
        {
            "question": "Who is the CEO of Aadi Bioscience?",
            "answer": "The CEO of Aadi Bioscience is Nina M. P. D. N. M. S. R. A. S. N. M. C. S. M. S. C. A. S. N. C. S. S. M. K. D. S. P. D. S. C."
        },
        {
            "question": "Where is Aadi Bioscience headquartered?",
            "answer": "Aadi Bioscience is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Aadi's main product?",
            "answer": "Aadi's main product candidate is AADI-001, a treatment for tumors with specific genetic mutations."
        },
        {
            "question": "When was Aadi Bioscience founded?",
            "answer": "Aadi Bioscience was founded in 2011."
        }
    ],
    "competitors": [
        "CLVS",
        "SRNE",
        "XLRN"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "PFE",
        "GILD"
    ]
}